Gastrointestinal Cancer

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.

Ramesh K. Ramanathan, MD, discusses emerging agents and the hurdles oncologists are facing in the field of pancreatic cancer.

Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.

Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.

Jonathan Strosberg, MD, discusses the overall findings of the NETTER-1 trial and the quality of life analysis in patients with midgut neuroendocrine tumors.

Rahmi Oklu, MD, PhD, discusses various approaches physicians use to treat patients who have CRC with liver metastases.

Lewis R. Roberts, MB, ChB, PhD, spoke on the current state of hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses updates in the gastric cancer landscape, biomarker developments, and agents emerging in the pipeline.

Axel Grothey, MD, discusses frontline therapy and maintenance strategies for patients with metastatic colorectal cancer.

Lewis R. Roberts, MB, ChB, PhD, professor of Medicine, Mayo Clinic, discusses the prevalence of hepatocellular carcinoma (HCC).

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses the identification of novel biomarkers in gastric cancer during the 2017 State of the Science Summit on Gastrointestinal Malignancies.

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

Robert J. Mayer, MD, who helped the field of oncology develop while conducting groundbreaking research, was honored in the Gastrointestinal Cancer category with a 2015 Giants of Cancer Care® award, a program that OncLive developed to recognize leaders in the field.

Researchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.

Tivantinib failed to improve overall survival compared with placebo as a second-line therapy for patients with MET-overexpressing inoperable hepatocellular carcinoma in the phase III METIV-HCC study.

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

The addition of a platinum agent to standard gemcitabine and nab-paclitaxel was found to be associated with impressive response and overall survival rates in patients with stage IV pancreatic cancer.

Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.